- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Big Pharma-backed MapLight plots IPO to advance neuro pipeline | ||
| Mo | Italy's Angelini inks $550M-plus pact for preclinical brain condition asset | ||
| Mo | Ionis plots FDA filing after rare neurological disease candidate posts phase 3 win | ||
| Mo | 'We have the will': Roche unveils strategy to become 'top 3' obesity company | ||
| Mo | Sanofi's troubled MS hopeful tolebrutinib hit by FDA delay | ||
| Mo | Pfizer inks $4.9B upfront Metsera buyout to beef up obesity pipeline following internal setbacks | ||
| Mo | Roche reports phase 3 breast cancer victory, starting key period for oral SERD with a win | ||
| Mo | Genfit ends liver failure program after seeing adverse event in phase 2 trial | ||
| Fr | Two years after Carmot buyout, what's next for Roche's expensive obesity pipeline? | ||
| Do | Moderna co-founder Robert Langer's son launches new VC with $77.5M, backing from dad | ||
| Do | Carisma Therapeutics' lifeline dissipates as reverse merger plans fall through, Moderna cuts ties | ||
| Do | Biogen strikes $85M Alcyone buyout, securing tech for spinal drug delivery | ||
| Do | VectorY pens $1.2B biobucks pact to use Shape's capsid to deliver gene therapies into brain | ||
| Do | Pfizer, Arvinas lose interest in commercializing PROTAC inhibitor, leading to layoffs at the biotech | ||
| Do | QL Biopharm links once-monthly GLP-1 to incumbent-rivaling weight loss in phase 2 | ||
| Do | Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug | ||
| Mi | VC Aditum launches cardiovascular biotech, offers Mabwell up to $1B for siRNA asset | ||
| Mi | J&J's IL-23 drug defeats reigning champ Sotyktu in phase 3 psoriasis trial | ||
| Mi | Regeneron reports phase 3 win in ultrarare disease, bouncing back to spark race to FDA | ||
| Mi | Lilly rounds out oral GLP-1 weight loss data, posts semaglutide-topping results in diabetes | ||
| Mi | Why Sanofi's R&D chief is 'pretty pragmatic' about a 'mixed' year of clinical development | ||
| Mi | Roivant reports phase 3 autoimmune win for ex-Pfizer asset | ||
| Mi | Innate to lose 30% of workforce, including CSO, in focus on 'highest-value assets' | ||
| Mi | Pharma tells Scotland how to court investment amid UK life sciences turmoil | ||
| 16.09. | Pharma execs cite 'challenging' environment during grilling by UK lawmakers over R&D pullback |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .